Envisagenics

📍 New York, United States🗓 Founded 2014👥 48 employees💰 Last funded Oct 2017
Biotechnology Research🌐 envisagenics.com
Website LinkedIn
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Envisagenics?
Envisagenics has 1 investors on record on gritt.io, 1 mid-stage.
When did Envisagenics last raise funding?
The most recent investment in Envisagenics recorded on gritt.io was in October 2017.
When was Envisagenics founded?
Envisagenics was founded in 2014.
What industry is Envisagenics in?
Envisagenics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Envisagenics based?
Envisagenics is headquartered in New York, United States.